<DOC>
	<DOCNO>NCT00117949</DOCNO>
	<brief_summary>Population pharmacokinetic pharmacodynamic data Study FE200486 CS06 FE200486 CS02 provide knowledge optimal dose regimen FE200486 ( degarelix ) . Both study guide dose selection phase III . In addition , safety tolerance data generate .</brief_summary>
	<brief_title>Study Investigating Pharmacokinetics , Pharmacodynamics Safety FE200486</brief_title>
	<detailed_description />
	<mesh_term>Prostatic Neoplasms</mesh_term>
	<criteria>Each patient must meet follow inclusion criterion entry study : Has give write consent study relate activity perform ( A study related activity define procedure would perform normal management patient . ) Is male patient histologically proven adenocarcinoma prostate ( stage ) endocrine treatment indicate , except neoadjuvant hormonal therapy . For patient , prostatespecific antigen ( PSA ) increase two consecutive determination least 2 week apart prior Visit 1 must document . Is least 18 year . Has ECOG score 2 . Has baseline testosterone level within age specific normal range measure central laboratory . Has PSA value 2 ng/mL measure central laboratory . Has life expectancy least 6 month . Any patient meeting one follow exclusion criterion enter study : Previous present hormonal management prostate cancer ( surgical castration hormonal manipulation , e.g . GnRH agonist , GnRH antagonists , antiandrogens , estrogen , PCSpec ) except neoadjuvant hormonal therapy &lt; 6 month duration complete &gt; 6 month prior Visit 1 . Requires hormonal therapy neoadjuvant purpose . Is recently ( within last 12 week precede Visit 1 ) presently treat drug modify testosterone level function . Is consider candidate curative therapy , i.e. , radical prostatectomy radiotherapy within 6 month Visit 1 . Has history severe asthma require daily treatment inhalation steroid , angioedema anaphylactic reaction . Has hypersensitivity towards component investigational product . Has cancer disease within last 10 year except prostate cancer , surgically remove basocellular squamous cell carcinoma skin . Has clinically significant neurologic , gastrointestinal , renal , hepatic , cardiovascular , psychological , pulmonary , metabolic , endocrine , hematological , dermatological infectious disorder condition , include excessive alcohol drug abuse , may interfere trial participation , may affect conclusion study , judge investigator . Any clinically significant laboratory abnormality , judgment investigator , would interfere patient 's participation study evaluation study result ( liver transaminase must within normal limit ) . Has mental incapacity language barrier preclude adequate understanding cooperation . Has receive investigational drug within last 12 week precede Visit 1 . Has previously participate study .</criteria>
	<gender>Male</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>May 2011</verification_date>
	<keyword>Prostate Cancer</keyword>
	<keyword>Androgen ablation therapy</keyword>
</DOC>